Aktieanalys

SynAct Pharma: New Indication Provides Diversification - Redeye

{newsItem.title}

Redeye Publicerad: 27 Jun 07:26

Redeye updates its base case of Synact following the directed share issue and new programme in polymyalgia rheumatica, which broadens resomelagon’s potential and diversifies its clinical development risk.

Länk till analysen i sin helhet: https://www.redeye.se/research/1116238/synact-pharma-new-indication-provides-diversification?utm_source=finwire&utm_medium=RSS

Nyheter om SynAct Pharma

Läses av andra just nu

Om aktien SynAct Pharma

Senaste nytt